Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model
Conclusions
This model projected that PHiD-CV would provide both incremental health benefits and cost-savings compared with PCV-13 at price parity. Using PHiD-CV could result in substantial budget savings to the NHS. These savings could be used to implement other life-saving interventions.
Source: BMJ Open - Category: Journals (General) Authors: Delgleize, E., Leeuwenkamp, O., Theodorou, E., Van de Velde, N. Tags: Open access, Global health, Health economics, Health policy, Infectious diseases, Paediatrics Research Source Type: research
More News: Economics | Epidemiology | General Medicine | Haemophilus Influenzae (Hib) | Infectious Diseases | Influenza Vaccine | Meningitis Vaccine | Otitis | Otitis Media | Pediatrics | Pneomococcal Vaccine | Pneumonia | Primary Care | UK Health | Vaccines